

1644

## PATENT

Case Docket No. UC067.002A

Date: January 8, 2002

Page 1



In re application of : SAXON et al.  
 App. No. : 09/847,208  
 Filed : May 1, 2001  
 For : FUSION MOLECULES  
       AND TREATMENT OF  
       IgE-MEDIATED  
       ALLERGIC DISEASES  
 Examiner : P. Huynh  
 Art Unit : 1644

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on

RECEIVED

January 8, 2002

(Date)

FEB 04 2002

Ginger R. Dreger, Reg. No. 33,055 TECH CENTER 1600/2900

**COMMISSIONER FOR PATENTS**  
**WASHINGTON, D.C. 20231**

Sir:

Transmitted herewith is an AMENDMENT AND RESPONSE in the above-identified application.

The fee has been calculated as shown below:

**CLAIMS AS FILED**

| CLAIMS<br>REMAINING<br>AFTER<br>AMENDMENT  | HIGHEST NO.<br>PREVIOUSLY<br>PAID FOR | PRESENT<br>EXTRA | RATE | ADDITIONAL<br>FEE                                      |
|--|---------------------------------------|------------------|------|--|
| Total Claims 33 —  | 72                                    | = 0 ×            | \$18 | = \$0  |
| Independent Claims 0 —   | 5                                     | = 0 ×            | \$84 | = \$0  |
| If application has been amended to contain multiple dependent claim(s), then add |                                       |                  |      | \$280 = \$0  |
| Time Extension Fee   |                                       |                  |      | \$0  |
|  |                                       |                  |      | <b>TOTAL ADDITIONAL FEE<br/>FOR THIS AMENDMENT \$0</b> |

- (X) Sequence Submission Statement, Sequence Listing in computer-readable form and paper copy of same.
- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

*Ginger R. Dreger*  
 Ginger R. Dreger  
 Registration No. 33,055  
 Attorney of Record

W:\DOCS\EJD\UC067.002A\EJD-1028.DOC  
 010802



10/c

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Saxon *et al.* ) Group Art Unit 1644  
 Appl. No. : 09/847,208 )  
 Filed : May 1, 2001 )  
 For : FUSION MOLECULES AND ) I hereby certify that this correspondence and all  
       TREATMENT OF IgE-MEDIATED ) marked attachments are being deposited with the  
       ALLERGIC DISEASES ) United States Postal Service as first-class mail in  
       ) an envelope addressed to: Assistant  
       Examiner : Phuong N. Huynh ) Commissioner for Patents, Washington, D.C.  
                                     ) 20231, on  
                                     ) January 8, 2002  
                                     ) (Date)  
                                     ) *Ginger R. Dreger*  
                                     ) Ginger R. Dreger, Reg. No. 33,055

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The present communication is responsive to the Office Action mailed on October 10, 2001 (Paper No. 7), which set a three month period for reply. Applicants respectfully request reconsideration of the application in view of the following Amendment, Remarks and Arguments.

AMENDMENT

In accordance with 37 C.F.R. § 1.121, please amend the application as follows.

IN THE SPECIFICATION:

Please delete the paragraph on page 2 consisting of lines 12 through 19, and replace it with the following substitute paragraph:

--Through the high-affinity IgE receptor, Fc $\epsilon$ RI, IgE plays key roles in an array of acute and chronic allergic reactions, including asthma, allergic rhinitis, atopic dermatitis, severe food allergies, chronic urticaria and angioedema, as well as the serious physiological condition of anaphylactic shock as results, for example, from bee stings or penicillin allergy. Binding of a

RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900